BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
- Conditions
- Colorectal CancerHead and Neck CancerNeoplasm Metastasis
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT00908024
- Locations
- 🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇨🇦Local Institution, Toronto, Ontario, Canada
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Drug-Drug Interaction Study in Healthy Subjects
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT00904059
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00901498
- Locations
- 🇺🇸
Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
- Conditions
- ShinglesHerpes Zoster
- Interventions
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT00900783
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT00898716
- Locations
- 🇯🇵
Local Institution, Chuo-Ku, Tokyo, Japan
Multiple-Ascending Dose Study
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 57
- Registration Number
- NCT00892840
- Locations
- 🇸🇪
Local Institution, Uppsala, Sweden
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 263
- Registration Number
- NCT00890890
- Locations
- 🇺🇸
Pivotal Research Centers, Peoria, Arizona, United States
🇺🇸Nyu Langone Medical Center, New York, New York, United States
🇺🇸Yale University School Of Medicine, New Haven, Connecticut, United States
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced Solid CancersMetastatic Cancer
- Interventions
- Drug: Cdc7-inhibitor
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT00886782
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇫🇷Local Institution, Villejuif Cedex, France
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
- Conditions
- Advanced Cancer, Various, NOS
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT00884546
- Locations
- 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Safety Study to Evaluate BMS-830216 in Healthy Subjects
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT00878020
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States